Clovis Oncology Announces 2013 Operating Results And Expands CO-1686 Development Program

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for its quarter and year ended December 31, 2013, and provided an update on the expected milestones for its clinical development programs for 2014.

“Importantly, we have been delighted to see encouraging activity at each of the CO-1686 hydrobromide salt (HBr) doses, and we are increasing the size of our expansion cohorts to swiftly build a larger clinical data set in our T790M+ cohorts” “2013 was obviously a great year for us and it has set the stage for what will be an even more important year for our company,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology.

Help employers find you! Check out all the jobs and post your resume.